


**AMENDMENTS TO THE CLAIMS**

Claims 1-10 canceled.

11. (New) Process for the preparation of the amorphous form of methyl (S)-(+)-(2-chlorophenyl)-2-(6, 7-dihydro-4*H*-thieno [3,2- c] pyridine-5-yl)-acetate hydrogensulfate of the formula



which comprises,

dissolving clopidogrel base in an “A” type solvent, adding sulfuric acid or a mixture of sulfuric acid and an “A” or “B” type solvent to the mixture, adding the obtained mixture containing clopidogrel hydrogensulfate to a “B” type solvent, and filtering, optionally washing and drying the obtained precipitate.

12. (New) Process according to Claim 1 which comprises using less polar aprotic solvents preferably halogenated solvents, more preferably dichloromethane, or dipolar aprotic solvents preferably ketones more preferably lower alkyl ketones; most preferably acetone,

as "A" type solvent, and  
aprotic solvents preferably ether type solvents, more preferably diethyl ether, tetrahydrofuran, diisopropyl ether, most preferably diisopropyl ether, or dipolar aprotic solvents, preferably ester type solvent, more preferably ethyl acetate, or apolar solvents preferably alkyl hydrocarbons more preferably cyclohexane, hexane, heptane, most preferably cyclohexane  
as "B" type solvent.

13. (New) Process according to Claim 1 which comprises, dissolving of clopidogrel base in dichloromethane, adding sulfuric acid to the solution, mixing the obtained solution with cyclohexane, then filtering the obtained precipitate.